

NAPA Research Progress Report

NAPA Advisory Council Meeting

Richard J. Hodes, M.D.
Director
National Institute on Aging


January 26, 2015

FY2015 Appropriations Update

- H.R. 83 – On December 16, 2014, the President signed into law the Consolidated and Further Continuing Appropriations Act, 2015, providing funding through September 30, 2015, as P.L. 113-235.
- NIA received an additional \$25 million in its budget for FY2015.
- Total NIA appropriation increased from \$1.172B in FY14 to \$1.198B in FY15.

NIA Appropriations FY 2005-2015

Current versus Constant, FY05 Base Year



NIA Budget Increase

Report language:

Alzheimer's Disease.-The agreement includes an increase of \$25,000,000 for NIA. In keeping with longstanding practice, the agreement does not recommend a specific amount of NIH funding for this purpose or for any other individual disease. Doing so would establish a dangerous precedent that could politicize the NIH peer review system. **Nevertheless, in recognition that Alzheimer's disease poses a serious threat to the Nation's long-term health and economic stability, the agreement expects that a significant portion of the recommended increase for NIA should be directed to research on Alzheimer's.** The exact amount should be determined by scientific opportunity of additional research on this disease and the quality of grant applications that are submitted for Alzheimer's relative to those submitted for other diseases.

NIA Budget Increase

- Report language acknowledged the \$25,000,000 increase in NIA's budget.
- No specific earmarks for AD were mandated, but the language states that "a significant portion of the recommended increase for NIA should be directed to research on Alzheimer's."
- Decisions about funding allocations should be determined by scientific opportunity and the quality of grant applications that are submitted for AD relative to those submitted for other diseases.

AD Bypass Budget


SEC. 230. Hereafter, for each fiscal year through fiscal year 2025, the Director of the National Institutes of Health shall **prepare and submit directly to the President for review and transmittal to Congress, after reasonable opportunity for comment, but without change, by the Secretary of Health and Human Services and the Advisory Council on Alzheimer's Research, Care, and Services, an annual budget estimate (including an estimate of the number and type of personnel needs for the Institutes) for the initiatives of the National Institutes of Health pursuant to the National Alzheimer's Plan**, as required under section 2(d)(2) of Public Law 111-375.

AD Bypass Budget

- Language in SEC. 230 of the FY2015 Appropriations Act requires a bypass budget for NIH Alzheimer's disease research to be submitted to the President.
- The HHS Secretary may review and comment, but not alter, the NIH budget submission.
- The budget will be estimated based on the NIH components of the National Alzheimer's Plan.
- NIH is in discussion re: how the development of the budget will proceed.

2015 Summit Update

- February 9th-10th, 2015
- National and international participation anticipated
- 500 attendees registered; a live videocast will be available
- G7 wrap-up on March 16-17, 2015 in Geneva (organized by the WHO)



IADRP Update

- The Canadian Institutes of Health Research is now officially part of the IADRP - their portfolio has been uploaded and they are listed as a member
 - Their data now comprise almost 10% of the current IADRP records
- CADRO has been adopted by the WHO for their upcoming portfolio analysis



IADRP by the numbers

- Alzheimer's Disease project data from across **27** NIH ICs
- Data from **32** public, private and international funding organizations representing **8** countries
- Approximately **6,000** unique projects
- An estimated **3,800** PIs working at approximately **1,000** institutions in **31** countries

Advances in ALS and FTD Genetics Workshop

- Held on November 14, 2014
- Shared progress on ongoing efforts in FTD and ALS human genetics research, with particular focus on genes that cause both FTD and ALS
- Discussed strategies to improve clinical assessments, enable meta-analyses across genetic data sets, and validate candidate disease alleles
- Co-hosted by NINDS, the Association for Frontotemporal Degeneration (AFTD), and the ALS Association (ALSA)

Alzheimer's Disease-Related Dementias (ADRD) 2016

- Organized by NINDS
- Dates: March 29-30, 2016
- Location: Natcher Conference Center, NIH Main Campus, Bethesda, MD
- Goals: Assess progress, revise and update ADRD 2013 recommendations